Literature DB >> 15099202

From ABO-incompatible human kidney transplantation to xenotransplantation.

Guy P J Alexandre1.   

Abstract

The development (in 1981) of a protocol for successful renal allotransplantation across ABO barriers is outlined. From this experience, the concept of "adaptation", subsequently termed "accommodation", was defined. It was then hypothesized that a similar approach might allow pig-to-human organ xenotransplantation. This hypothesis was explored in the pig-to-baboon renal transplantation model, with graft survival for a maximum of 23 days. Rejection episodes were temporarily reversed, providing encouragement that discordant xenotransplantation would one day prove successful. Finally, the preparation of the thymokidney, developed as a means of inducing xenotolerance, is briefly reviewed. Copyright Blackwell Munksgaard, 2004

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15099202     DOI: 10.1111/j.1399-3089.2004.00105.x

Source DB:  PubMed          Journal:  Xenotransplantation        ISSN: 0908-665X            Impact factor:   3.907


  3 in total

1.  Upregulation of CD59: potential mechanism of accommodation in a large animal model.

Authors:  Adam D Griesemer; Masayoshi Okumi; Akira Shimizu; Shannon Moran; Yoshinori Ishikawa; Justin Iorio; J Scott Arn; Kazuhiko Yamada
Journal:  Transplantation       Date:  2009-05-15       Impact factor: 4.939

2.  Initial in vitro investigation of the human immune response to corneal cells from genetically engineered pigs.

Authors:  Hidetaka Hara; Naoko Koike; Cassandra Long; Jordan Piluek; Danny S Roh; Nirmala SundarRaj; James L Funderburgh; Yoshiaki Mizuguchi; Kumiko Isse; Carol J Phelps; Suyapa F Ball; David L Ayares; David K C Cooper
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-07-15       Impact factor: 4.799

Review 3.  The role of genetically engineered pigs in xenotransplantation research.

Authors:  David K C Cooper; Burcin Ekser; Jagdeece Ramsoondar; Carol Phelps; David Ayares
Journal:  J Pathol       Date:  2015-10-07       Impact factor: 7.996

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.